RepliCel Life Sciences
Financials
Estimates*
| CAD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | - |
| % growth | - | (53 %) | 111 % | - | - | - | - |
| EBITDA | (6.0m) | (2.7m) | (2.9m) | (1.1m) | (3.2m) | (<1m) | - |
| % EBITDA margin | (1693 %) | (1607 %) | (814 %) | (323 %) | (896 %) | (54 %) | - |
| Profit | (6.0m) | (2.8m) | (3.0m) | (1.6m) | (4.1m) | (<1m) | - |
| % profit margin | (1700 %) | (1660 %) | (849 %) | (447 %) | (1152 %) | (210 %) | - |
| EV / revenue | 22.3x | 43.3x | 25.8x | 22.1x | 26.1x | 9.3x | - |
| EV / EBITDA | -1.3x | -2.7x | -3.2x | -6.8x | -2.9x | -17.2x | - |
| R&D budget | 2.5m | <1m | 2.2m | <1m | 1.1m | <1m | - |
| R&D % of revenue | 719 % | 423 % | 621 % | 232 % | 325 % | 176 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $867k | Seed | |
| N/A | $70.0k | Seed | |
| N/A | N/A | IPO | |
| N/A | $143k | Post IPO Equity | |
| N/A | $267k | Post IPO Equity | |
$5.1m | Post IPO Equity | ||
| N/A | CAD2.7m | Post IPO Equity | |
* | N/A | CAD1.0m | Post IPO Debt |
| Total Funding | €852k | ||
Related Content
Recent News about RepliCel Life Sciences
EditRepliCel Life Sciences Inc. is a biotechnology company specializing in regenerative medicine, focusing on developing treatments for hair loss, skin aging, and tendon injuries. The company operates in the healthcare and life sciences market, targeting patients suffering from androgenic alopecia, skin aging, and tendon injuries. RepliCel's business model revolves around research and development, clinical trials, and partnerships with healthcare providers and pharmaceutical companies. The company generates revenue through licensing agreements, milestone payments, and royalties from its proprietary technologies. RepliCel's core products include RCH-01 for hair regrowth, RCS-01 for skin rejuvenation, and RCT-01 for tendon repair. These products leverage the body's own cells to promote healing and regeneration, offering a natural and effective solution for patients. RepliCel's innovative approach and commitment to science position it as a leader in the regenerative medicine field.
Keywords: regenerative medicine, hair growth, skin rejuvenation, tendon repair, biotechnology, clinical trials, licensing, partnerships, healthcare, life sciences.